An analysis shows Tandem’s Control-IQ automated insulin delivery system boosts time in range by three hours per day, largely due to the system's auto-correction feature.
The study published in Diabetes Technology & Therapeutics showed that time in range (TIR) improvements from the hybrid-closed loop technology were seen among all participants, regardless of age, race, income, starting A1C, or prior use of diabetes technology.
The meta-analysis of 3 studies included data from 369 people with type 1 diabetes from ages 2 to 72 years, 256 of whom used the Control-IQ system. This data was compared to glucose data mostly from people using a pump without the Control-IQ algorithm, although some injected insulin multiple times per day. Regardless, all participants wore Dexcom G6 continuous glucose monitors (CGM) to track their glucose levels.